European monoclonal antibodies market is estimated to grow at a CAGR of 7.2% during the forecast period. An increasing approval for monoclonal antibodies has been reported in the region, owing to the rising demand for novel monoclonal antibody therapies with higher safety and efficacy in the region. For instance, in June 2020, the European Commission has approved Sarclisa (isatuximab), a monoclonal antibody along with pomalidomide and dexamethasone (pom-dex) to treat adult patients suffering from relapsed and refractory multiple myeloma. These are intended for multiple myeloma patients who have received a minimum of two prior therapies such as a proteasome inhibitor and lenalidomide and have shown the progression of the condition on the last therapy.
To Request a Sample of our Report on European Monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/european-monoclonal-antibodies-market
As a monoclonal antibody, Sarclisa attaches to a particular epitope on the CD38 receptor of multiple myeloma cells. This approval offers a crucial additional therapeutic alternative and will offer a new treatment for myeloma patients who require new potential treatments as their disease has become refractory to their earlier treatment disease or has returned. Sarclisa along with pom-dex shown median progression-free survival of approximately one year. The launch of novel monoclonal antibodies therapies will lead to drive safety and effectiveness of the therapy, which in turn, will further accelerate the market growth.
Scope of the European Monoclonal Antibodies Market
Market Coverage
· Market number available for 2019-2026
· Base year- 2019
· Forecast period- 2020-2026
· Segment Covered- By Source and Application
· Countries Covered- UK, Germany, France, Spain, Italy, and Rest of Europe
· Competitive Landscape- AstraZeneca plc, Pfizer Inc., Sitryx Therapeutics Ltd., Orchard Therapeutics plc, and Mylan N.V.
Recent Strategic Initiatives in the European Monoclonal Antibodies Market
· In April 2020, Pfizer Inc. declared the European Commission approval of RUXIENCE (rituximab). It is a monoclonal antibody and biosimilar to MabThera (rituximab), which aims to treat granulomatosis with polyangiitis, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, rheumatoid arthritis, microscopic polyangiitis, and pemphigus vulgaris. The biosimilars’ approval including RUXIENCE is an essential development to treat certain cancers and autoimmune conditions. It offers effectiveness to improve access to treatment access while minimizing healthcare costs.
· In January 2020, Roche declared that the European Commission has permitted conditional marketing authorization for Polivy (polatuzumab vedotin), along with bendamustine plus MabThera (rituximab) (BR), to treat adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant.
(Get 15% Discount on Buying this Report)
A full Report of European Monoclonal Antibodies Market is Available at: https://www.omrglobal.com/industry-reports/european-monoclonal-antibodies-market
European Monoclonal Antibodies Market-Segmentation
By Source
· Murine
· Chimeric
· Human
· Humanized
By Application
· Cancer
· Infectious Diseases
· Auto-Immune Diseases
· Inflammatory Diseases
· Others
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
